Home » Stocks » THTX

Theratechnologies Inc. (THTX)

Stock Price: $2.23 USD -0.06 (-2.62%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $2.22 -0.01 (-0.45%) Jan 27, 7:46 AM
Market Cap 208.26M
Revenue (ttm) 47.53M
Net Income (ttm) -9.40M
Shares Out 61.01M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE 55.87
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.23
Previous Close $2.29
Change ($) -0.06
Change (%) -2.62%
Day's Open 2.32
Day's Range 2.19 - 2.33
Day's Volume 366,809
52-Week Range 1.43 - 3.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c...

GlobeNewsWire - 1 week ago

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

GlobeNewsWire - 1 week ago

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 2 weeks ago

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

GlobeNewsWire - 2 weeks ago

Expects record Q4 and FY 2020 revenues

GlobeNewsWire - 1 month ago

I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

GlobeNewsWire - 2 months ago

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 2 months ago

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 2 months ago

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 2 months ago

MONTREAL, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 3 months ago

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 3 months ago

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 3 months ago

MONTREAL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...

GlobeNewsWire - 3 months ago

MONTREAL, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter e...

GlobeNewsWire - 3 months ago

MONTREAL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization o...

GlobeNewsWire - 4 months ago

MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...

GlobeNewsWire - 4 months ago

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021

GlobeNewsWire - 4 months ago

First commercial launch in Europe

GlobeNewsWire - 5 months ago

MONTREAL, July 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe D...

Seeking Alpha - 6 months ago

Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 6 months ago

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat

GlobeNewsWire - 6 months ago

MONTREAL, July 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting o...

Seeking Alpha - 6 months ago

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020-

GlobeNewsWire - 6 months ago

sBLA expected to be filed in early 2022

GlobeNewsWire - 6 months ago

MONTREAL, July 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that dat...

GlobeNewsWire - 7 months ago

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor

GlobeNewsWire - 8 months ago

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904

GlobeNewsWire - 9 months ago

MONTREAL, April 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lé...

Seeking Alpha - 9 months ago

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

New sub-analysis of MGH Study presented at CROI 2020 New sub-analysis of MGH Study presented at CROI 2020

Seeking Alpha - 11 months ago

Theratechnologies Inc. (THTX) CEO Luc Tanguay on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

MONTREAL, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the sign...

GlobeNewsWire - 1 year ago

MONTREAL, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary reve...

About THTX

Theratechnologies, a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple neg... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1993
CEO
Paul Levesque
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
THTX
Full Company Profile

Financial Performance

In 2019, THTX's revenue was 63.22 million, an increase of 39.81% compared to the previous year's 45.22 million. Losses were -12.50 million, 165.9% more than in 2018.

Financial numbers in millions CAD.
Financial Statements